Alphamab Oncology (9966.HK)
Develops cancer treatment drugs using antibody technology for Chinese patients
7.67-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-18.7%
The outlook
Alphamab Oncology trades near its 52-week low at 7.67, with analyst targets averaging about 28% higher. The stock sits mixed against its moving averages, and the overall sentiment leans bearish based on current market positioning.
What’s behind the score
Price trendMixed vs its moving averages
52-week range15% of the way from its 52-week low to high
Price targetAvg target +28% vs current price
Market cap
$7.43B
52-wk high
15.75
52-wk low
6.23
50-day avg
7.66
200-day avg
9.39
Trailing P/E
—